Ratings by Cantor Fitzgerald (Steven Seedhouse)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 5/14/2025 | Astria Therapeutics | ATXS | Maintain | Overweight (Overweight) |
|
Details | ||
| 4/29/2025 | Inflarx NV | IFRX | New Coverage | Overweight (N/A) |
1.30 (0.80) |
-38.46% | Details | |
| 4/29/2025 | ProQR Therapeutics N.V. | PRQR | New Coverage | Overweight (N/A) |
1.43 (1.94) |
35.66% | Details | |
| 4/29/2025 | Alnylam Pharmaceuticals | ALNY | New Coverage | Neutral (N/A) |
251.56 (304.67) |
21.11% | Details | |
| 4/29/2025 | Pharvaris B.V. | PHVS | New Coverage | Overweight (N/A) |
16.84 (17.23) |
2.32% | Details | |
| 4/29/2025 | BioCryst Pharma | BCRX | New Coverage | Overweight (N/A) |
8.39 (10.40) |
23.96% | Details | |
| 4/29/2025 | Viking Therapeutic | VKTX | New Coverage | Overweight (N/A) |
24.99 (28.58) |
14.37% | Details | |
| 4/29/2025 | Apellis Pharmaceuticals | APLS | New Coverage | Overweight (N/A) |
17.49 (19.26) |
10.12% | Details | |
| 4/29/2025 | Editas Medicine | ATXS | New Coverage | Overweight (N/A) |
1.54 (5.60) |
263.64% | Details |
